LXRX Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -3703.49% compared to Lexicon Pharmaceuticals's net margin of --. Lexicon Pharmaceuticals's return on equity of -115.11% beat Perspective Therapeutics's return on equity of --.

Lexicon Pharmaceuticals has a consensus price target of $3.60, signalling upside risk potential of 375.06%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Perspective Therapeutics has higher upside potential than Lexicon Pharmaceuticals, analysts believe Perspective Therapeutics is more attractive than Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals has a beta of 1.069, which suggesting that the stock is 6.862% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Lexicon Pharmaceuticals quarterly revenues are $1.8M, which are larger than Perspective Therapeutics quarterly revenues of --. Lexicon Pharmaceuticals's net income of -$64.8M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 42.13x versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Halozyme Therapeutics has a net margin of -3703.49% compared to Lexicon Pharmaceuticals's net margin of 47.23%. Lexicon Pharmaceuticals's return on equity of -115.11% beat Halozyme Therapeutics's return on equity of 156.62%.

Lexicon Pharmaceuticals has a consensus price target of $3.60, signalling upside risk potential of 375.06%. On the other hand Halozyme Therapeutics has an analysts' consensus of $64.13 which suggests that it could grow by 34.89%. Given that Lexicon Pharmaceuticals has higher upside potential than Halozyme Therapeutics, analysts believe Lexicon Pharmaceuticals is more attractive than Halozyme Therapeutics.

Lexicon Pharmaceuticals has a beta of 1.069, which suggesting that the stock is 6.862% more volatile than S&P 500. In comparison Halozyme Therapeutics has a beta of 1.226, suggesting its more volatile than the S&P 500 by 22.555%.

Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. Halozyme Therapeutics pays out -- of its earnings as a dividend.

Lexicon Pharmaceuticals quarterly revenues are $1.8M, which are smaller than Halozyme Therapeutics quarterly revenues of $290.1M. Lexicon Pharmaceuticals's net income of -$64.8M is lower than Halozyme Therapeutics's net income of $137M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while Halozyme Therapeutics's PE ratio is 15.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 42.13x versus 6.52x for Halozyme Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -3703.49% compared to Lexicon Pharmaceuticals's net margin of -27.76%. Lexicon Pharmaceuticals's return on equity of -115.11% beat Quanterix's return on equity of -11.45%.

Lexicon Pharmaceuticals has a consensus price target of $3.60, signalling upside risk potential of 375.06%. On the other hand Quanterix has an analysts' consensus of $21.80 which suggests that it could grow by 107.22%. Given that Lexicon Pharmaceuticals has higher upside potential than Quanterix, analysts believe Lexicon Pharmaceuticals is more attractive than Quanterix.

Lexicon Pharmaceuticals has a beta of 1.069, which suggesting that the stock is 6.862% more volatile than S&P 500. In comparison Quanterix has a beta of 1.300, suggesting its more volatile than the S&P 500 by 29.975%.

Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Lexicon Pharmaceuticals quarterly revenues are $1.8M, which are smaller than Quanterix quarterly revenues of $34.1M. Lexicon Pharmaceuticals's net income of -$64.8M is lower than Quanterix's net income of -$9.5M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 42.13x versus 3.12x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of -3703.49% compared to Lexicon Pharmaceuticals's net margin of 2.53%. Lexicon Pharmaceuticals's return on equity of -115.11% beat Viatris's return on equity of -4.39%.

Lexicon Pharmaceuticals has a consensus price target of $3.60, signalling upside risk potential of 375.06%. On the other hand Viatris has an analysts' consensus of -- which suggests that it could grow by 8.47%. Given that Lexicon Pharmaceuticals has higher upside potential than Viatris, analysts believe Lexicon Pharmaceuticals is more attractive than Viatris.

Lexicon Pharmaceuticals has a beta of 1.069, which suggesting that the stock is 6.862% more volatile than S&P 500. In comparison Viatris has a beta of 0.964, suggesting its less volatile than the S&P 500 by 3.557%.

Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 3.87% to investors and pays a quarterly dividend of $0.12 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. Viatris pays out 1052.29% of its earnings as a dividend.

Lexicon Pharmaceuticals quarterly revenues are $1.8M, which are smaller than Viatris quarterly revenues of $3.8B. Lexicon Pharmaceuticals's net income of -$64.8M is lower than Viatris's net income of $94.8M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 42.13x versus 0.99x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.